UROVANT SCIENCES INC
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$9.2M
Doctors Paid
9,422
Transactions
38,771
2022 Total
$7.2M
Payment Breakdown by Category
Research$7.0M (75.6%)
Food & Beverage$767,926 (8.3%)
Consulting$305,443 (3.3%)
Travel$232,117 (2.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $7.0M | 1,070 | 75.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $924,862 | 502 | 10.0% |
| Food and Beverage | $767,926 | 35,981 | 8.3% |
| Consulting Fee | $305,443 | 158 | 3.3% |
| Travel and Lodging | $232,117 | 963 | 2.5% |
| Space rental or facility fees (teaching hospital only) | $8,000 | 2 | 0.1% |
| Education | $3,430 | 90 | 0.0% |
| Honoraria | $2,448 | 5 | 0.0% |
Payments by Type
Research
$7.0M
1,070 transactions
General
$2.2M
37,701 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) | $4.6M | 0 | 455 |
| Composur, A Patient-centric, Phase IV, Open-label, Prospective, Real World US Study to Evaluate Vibegron on Patient Treatment Satisfaction, Quality of Life, and Healthcare Resource Utilization in Overactive Bladder | $700,844 | 0 | 251 |
| A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) | $490,024 | 0 | 110 |
| An Exploratory Phase 2a Study Evaluating the Efficacy and Safety of URO-902 in Subjects With Overactive Bladder and Urge Urinary Incontinence | $468,080 | 0 | 225 |
| AnOpen-Label, Randomized, Crossover, Single Dose Study to Assess thePharmacokinetics and Safety of Vibegron TabletandGranuleFormulations | $426,237 | 0 | 13 |
| An open-label, randomized, croosover, single dose study to assess the pharmacokinetics and saftey of vibegron tablet and granule formulations | $230,828 | 0 | 11 |
| A Phase 2/3, Open-label, Baseline-controlled, Multicenter, Long-term Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age with Neurogenic Detrusor Overactivity (NDO) on Clean Intermittent Catheterization (CIC) | $7,500 | 0 | 1 |
| A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB) (Empowur) | $5,000 | 0 | 1 |
| Composur | $1,976 | 0 | 3 |
Payments by Medical Specialty
Top Paid Doctors — Page 8
| Doctor | Specialty | Location | Total | 2022 |
|---|---|---|---|---|
| Adam Kaplan, M.d, M.D | Urology | Santa Rosa, CA | $419.26 | $0 |
| Dr. Matthew Rainwater, M.d, M.D | Surgery | Fresno, CA | $417.74 | $0 |
| Marcelino Albuerne, M.d, M.D | Geriatric Medicine | Catonsville, MD | $416.14 | $0 |
| Lindsey Rector | Physician Assistant | Baltimore, MD | $414.96 | $0 |
| Lyudmila Emag, Np, NP | Adult Health | Brooklyn, NY | $413.13 | $0 |
| Yuly Chalik, Md, MD | Specialist | Brooklyn, NY | $411.19 | $0 |
| Dr. Gene Braga, M.d, M.D | Urology | Somers Point, NJ | $411.02 | $0 |
| Ally Gordon, Pa-C, PA-C | Physician Assistant | Owings Mills, MD | $410.62 | $0 |
| Mrs. Kathleen Scott, Pa-C, PA-C | Physician Assistant | Cleveland, OH | $410.00 | $0 |
| Ben Jacobs, Md, MD | Urology | Brooklyn, NY | $409.94 | $0 |
| Emma Latimore, Pa-C, PA-C | Physician Assistant | Oak Ridge, TN | $407.30 | $0 |
| Dr. Jonathan Vapnek, M.d, M.D | Urology | New York, NY | $407.07 | $0 |
| Nagai Rajendran, Md, MD | Urology | Yonkers, NY | $405.47 | $0 |
| Mathew Fakhoury, Do, DO | Urology | Yonkers, NY | $403.76 | $0 |
| Mr. Chris Threatt, Md, MD | Urology | Redwood City, CA | $401.65 | $0 |
| Jason Meade, Do, DO | Urogynecology and Reconstructive Pelvic Surgery | Fresno, CA | $400.69 | $0 |
| Dr. Paul Hatcher, Md, MD | Urology | Knoxville, TN | $399.34 | $0 |
| Ashley Ruane, Crnp, CRNP | Nurse Practitioner | Scranton, PA | $398.28 | $0 |
| Katie Gillies, Pa-C, PA-C | Physician Assistant | Winfield, IL | $398.15 | $0 |
| Dr. Antonio Ruiz, M.d, M.D | Internal Medicine | Shavano Park, TX | $394.94 | $0 |
| Miss. Sandra Rizzo, Crnp, CRNP | Urology | Frederick, MD | $394.86 | $0 |
| Dr. Anshu Guleria, M.d, M.D | Urology | Manassas, VA | $393.80 | $0 |
| Laurie Kane, Md, MD | Urogynecology and Reconstructive Pelvic Surgery | Manahawkin, NJ | $393.52 | $0 |
| Dr. Alejandro Rodriguez, M.d, M.D | Urology | Columbia, MD | $392.44 | $0 |
| Dr. Cynthia Moorman, M.d, M.D | Urology | Frederick, MD | $391.06 | $0 |
About UROVANT SCIENCES INC
UROVANT SCIENCES INC has made $9.2M in payments to 9,422 healthcare providers, recorded across 38,771 transactions in the CMS Open Payments database. In 2022, the company paid $7.2M. The top product by payment volume is GEMTESA ($8.7M).
Payments were distributed across 123 medical specialties. The top specialty by payment amount is Urology ($899,546 to 3,135 doctors).
Payment categories include: Food & Beverage ($767,926), Consulting ($305,443), Research ($7.0M), Travel & Lodging ($232,117).
UROVANT SCIENCES INC is associated with 1 products in the CMS Open Payments database.